AusBiotech acknowledges the substantial contribution of Warren Bingham as Chair of the AusMedtech National Advisory Group as he steps down after extended service and welcomes newly-appointed Chair, Mr David Cain.
Dedicated to the development, growth and prosperity of the Australian medical technology industry, AusMedtech provides initiatives to facilitate success in product development, manufacturing, commercialisation, export success and representation on industry issues. It works to:
- Provide information to assist better decision-making by medical technology businesses to facilitate success in product development, manufacturing and business;
- Represent the Australian developers and manufactures and focus the industry on commercialisation and export success – taking Australian medical technology to the world;
- Support future sustainability by encouraging links between industry, research bodies and government; and
- Be the leading advocate for industry issues and raise community awareness of the Australian medical technology industry.
David Cain is Senior Government Affairs and Policy Manager at Johnson & Johnson and a healthcare expert who is actively involved with industry committees including: AmCham, CEDA, AFGC, MTAA, and ACCORD. David has been on the AusMedtech National Advisory Group for some years, bringing his vast knowledge of health financing – including prostheses in private and public hospitals, diagnostic equipment, health care professional influences and self-medication/preventative health investments.
Warren Bingham has been Chair of the AusMedtech National Advisory Group for almost five years. Warren is the Director and Chief Operating Officer, Future Asset Management International and founder and Executive Chairman of MedTech International - a medical technologies consultancy specialising in leading organisations with innovative, first to market and disruptive medical technologies with their global and domestic strategic planning, in market commercialisation, Board fulfilment and profitable execution.
With more than 25 years of proven experience and success in the life sciences sector, Warren also manages an extensive portfolio in the NFP sector, providing strategic advice, board and ambassadorship, and hands on volunteering for more than 10 charities and NFP organisations.
AusBiotech CEO, Mr Glenn Cross, said: “Warren has made a great contribution to AusMedtech over the past decade that he has been working on committees with AusBiotech and his years of leadership Chairing AusMedtech National Advisory Group. He was responsible for setting up AusMedtech Health Economics Expert Panel and the AusMedtech Regulatory Affairs Expert Panel.”
The sub-committees enabled a cross-section of representatives from small to large Australian medical device companies, overseas manufacturers and suppliers, regulatory and industry consultants.
“The Panel and its sub-committees enabled us to be more active in advocacy related to regulatory processes, approvals and reimbursement for medical devices and diagnostics in Australia, and thereby more supportive to emerging medical technologies."
“We warmly welcome David Cain to Chair role. With a 360-degree knowledge of health systems, David is a high-impact communicator, trusted thought-leader, advisor and a recognised industry leader with a collegiate style,” said Mr Cross.